1. Home
  2. MIRA vs MYNZ Comparison

MIRA vs MYNZ Comparison

Compare MIRA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRA
  • MYNZ
  • Stock Information
  • Founded
  • MIRA 2020
  • MYNZ 2021
  • Country
  • MIRA United States
  • MYNZ Germany
  • Employees
  • MIRA N/A
  • MYNZ N/A
  • Industry
  • MIRA Biotechnology: Pharmaceutical Preparations
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIRA Health Care
  • MYNZ Health Care
  • Exchange
  • MIRA Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • MIRA 17.1M
  • MYNZ N/A
  • IPO Year
  • MIRA 2023
  • MYNZ 2021
  • Fundamental
  • Price
  • MIRA $1.05
  • MYNZ $0.31
  • Analyst Decision
  • MIRA Strong Buy
  • MYNZ Buy
  • Analyst Count
  • MIRA 2
  • MYNZ 2
  • Target Price
  • MIRA $14.00
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • MIRA 552.1K
  • MYNZ 2.3M
  • Earning Date
  • MIRA 11-11-2024
  • MYNZ 11-14-2024
  • Dividend Yield
  • MIRA N/A
  • MYNZ N/A
  • EPS Growth
  • MIRA N/A
  • MYNZ N/A
  • EPS
  • MIRA N/A
  • MYNZ N/A
  • Revenue
  • MIRA N/A
  • MYNZ $917,203.00
  • Revenue This Year
  • MIRA N/A
  • MYNZ $36.69
  • Revenue Next Year
  • MIRA N/A
  • MYNZ $91.67
  • P/E Ratio
  • MIRA N/A
  • MYNZ N/A
  • Revenue Growth
  • MIRA N/A
  • MYNZ 16.23
  • 52 Week Low
  • MIRA $0.51
  • MYNZ $0.19
  • 52 Week High
  • MIRA $6.40
  • MYNZ $3.39
  • Technical
  • Relative Strength Index (RSI)
  • MIRA 38.97
  • MYNZ 51.63
  • Support Level
  • MIRA $1.04
  • MYNZ $0.28
  • Resistance Level
  • MIRA $1.20
  • MYNZ $0.33
  • Average True Range (ATR)
  • MIRA 0.07
  • MYNZ 0.05
  • MACD
  • MIRA 0.02
  • MYNZ 0.00
  • Stochastic Oscillator
  • MIRA 19.44
  • MYNZ 42.69

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Share on Social Networks: